HER2-PDL1

N/A

Report date: 2025/01/26 16:10:57

Base Information

Drug NameHER2-PDL1
Drug Alias Namedual PD-L1 checkpoint inhibitor/anti-HER2 bispecific antibody (Shandong Fontacea Pharmaceutical)HER2-PDL1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShandong Fontacea Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Fontacea Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A